| Target General Information |
| Target ID |
T49031
|
| Target Name |
Proteasome subunit beta type-5 (PSMB5) |
| Gene Name |
PSMB5 |
| Species |
Homo sapiens |
| UniProt ID |
PSB5_HUMAN |
| Sequence |
MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPGWGVPEEPGIEMLHGT
TTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWERLLAR
QCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDSEGNRI
SGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQATYRDAYSGGAVNLYHVRE
DGWIRVSSDNVADLHEKYSGSTP [Homo sapiens]
|
| Drug and Corresponding Resistance Mutations |
| Mutation Info |
Missense: A49T |
| Drugs |
| Drug Name |
Bortezomib |
Drug Info
|
[2] |
| Targeted Disease |
Myeloma; T lymphoblastic lymphoma/leukemia |
|
| Drug Name |
PR-924 |
Drug Info
|
[1] |
| Targeted Disease |
T lymphoblastic lymphoma/leukemia |
|
| Mutation Info |
Missense: A49V |
| Drugs |
| Drug Name |
Bortezomib |
Drug Info
|
[2] |
| Targeted Disease |
Myeloma; T lymphoblastic lymphoma/leukemia |
|
| Mutation Info |
Missense: A50V |
| Drugs |
| Drug Name |
Bortezomib |
Drug Info
|
[2] |
| Targeted Disease |
Myeloma; T lymphoblastic lymphoma/leukemia |
|
| Mutation Info |
Missense: C52F |
| Drugs |
| Drug Name |
Bortezomib |
Drug Info
|
[1] |
| Targeted Disease |
Myeloma; T lymphoblastic lymphoma/leukemia |
|
| Mutation Info |
Missense: M45I |
| Drugs |
| Drug Name |
PR-924 |
Drug Info
|
[1] |
| Targeted Disease |
T lymphoblastic lymphoma/leukemia |
|
| Mutation Info |
Missense: M45V |
| Drugs |
| Drug Name |
PR-924 |
Drug Info
|
[1] |
| Targeted Disease |
T lymphoblastic lymphoma/leukemia |
|
| References |
| REF 1 |
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.Biochem Pharmacol.2014 May 1;89(1):43-51.
|
| REF 2 |
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.Exp Hematol.2009 Jul;37(7):831-7.
|
